AN ACT TO REQUIRE THAT HEALTH BENEFIT PLANS AND PRESCRIPTION DRUG PROGRAMS THAT PROVIDE COVERAGE FOR PRESCRIPTION DRUGS AND RECEIVE MANUFACTURER COPAY ASSISTANCE FOR A PRESCRIPTION DRUG MUST APPLY THE VALUE OF THE COPAY ASSISTANCE TO REDUCE OR LIMIT THE AMOUNT THAT A PATIENT PAYS FOR A PRESCRIPTION DRUG AND/OR APPLY THE VALUE OF SUCH ASSISTANCE TO A PATIENT'S ANNUAL COST-SHARING REQUIREMENTS, SUCH AS DEDUCTIBLES AND OUT-OF-POCKET MAXIMUM COSTS; TO BRING FORWARD SECTIONS 83-9-5 AND 83-9-6.1, MISSISSIPPI CODE OF 1972, WHICH RELATE TO ACCIDENT AND HEALTH INSURANCE, FOR THE PURPOSES OF POSSIBLE AMENDMENT; AND FOR RELATED PURPOSES.
Impact
The bill's implications extend to all health benefit plans that provide coverage for prescription drugs in Mississippi. By mandating that copay assistance be utilized to lower patient costs, the bill aims to foster a more equitable healthcare system, ensuring that financial assistance from manufacturers directly benefits patients at the pharmacy checkout. The long-term goal is to potentially increase access to necessary medications for a broader demographic, particularly those financially strained by high drug costs.
Summary
House Bill 1667 aims to require that health benefit plans and prescription drug programs applying manufacturer copay assistance must apply the value of this assistance to reduce the amount a patient pays for their prescription drugs. This bill focuses on alleviating the financial burden on patients by limiting their out-of-pocket costs based on the copay assistance they receive. The legislation is designed to ensure that patients' annual cost-sharing requirements, such as deductibles and out-of-pocket maximum costs, are also reduced accordingly.
Contention
Despite its benefits, there are concerns surrounding the enforcement and encapsulation of such provisions by health insurers. Critics highlight the potential for insurers to respond with increased premiums or reduced coverage options to offset the financial impacts of curtailing out-of-pocket costs. Moreover, it raises questions about how effectively the bill can be implemented and monitored by relevant state authorities, including the Office of Attorney General, which is designated to enforce these new requirements.